Table 4.

Select ongoing trials with CAR T-cell therapy for patients with ALL relapsed/refractory B acute lymphoblastic leukemia.

Trial	Phase	Treatment	Population	Endpoints
OBERON (NCT03628053)	III	Tisagenlecleucel vs. blinatumomab or inotuzumabozogamicin	Adults with B-cell precursor ALL; R/R after 1–2 lines of therapy or ASCT	OS
CASSIOPEIA (NCT03876769)	II	Tisagenlecleucel	Pediatric/young adult high-risk B-cell ALL; MRD positive after first-line therapy	DFS
ZUMA-4 (NCT02625480)	I/II	Axicabtageneciloleucel	Pediatric/adolescent pts with R/R B-precursor ALL or R/R B-cell NHL	AEs, CRR, ORR